Last reviewed · How we verify
ALX-0061
ALX-0061 is a nanobody targeting IL-17A and IL-17F, which are pro-inflammatory cytokines involved in autoimmune diseases.
ALX-0061 is a nanobody targeting IL-17A and IL-17F, which are pro-inflammatory cytokines involved in autoimmune diseases. Used for Psoriasis, Ankylosing spondylitis.
At a glance
| Generic name | ALX-0061 |
|---|---|
| Also known as | Vobarilizumab |
| Sponsor | Ablynx, a Sanofi company |
| Drug class | IL-17 inhibitor |
| Target | IL-17A, IL-17F |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By binding to both IL-17A and IL-17F, ALX-0061 inhibits their interaction with the IL-17 receptor, reducing inflammation and the associated symptoms in autoimmune conditions.
Approved indications
- Psoriasis
- Ankylosing spondylitis
Common side effects
- Infections
- Injection site reactions
Key clinical trials
- A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis (PHASE2)
- A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis (PHASE2)
- An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis (PHASE2)
- A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus (PHASE2)
- Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients (PHASE1, PHASE2)
- ALX-0061 Phase I Bioavailability Study in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALX-0061 CI brief — competitive landscape report
- ALX-0061 updates RSS · CI watch RSS
- Ablynx, a Sanofi company portfolio CI